BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lambert A, Schwarz L, Ducreux M, Conroy T. Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer. Cancers (Basel) 2021;13:4724. [PMID: 34572951 DOI: 10.3390/cancers13184724] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Li X, Huang J, Jiang C, Chen P, Quan Q, Jiang Q, Li S, Guo G. Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis. Eur J Clin Pharmacol 2023;79:323-40. [PMID: 36576528 DOI: 10.1007/s00228-022-03441-9] [Reference Citation Analysis]
2 Molla MHR, Aljahdali MO, Sumon MAA, Asseri AH, Altayb HN, Islam MS, Alsaiari AA, Opo FADM, Jahan N, Ahammad F, Mohammad F. Integrative Ligand-Based Pharmacophore Modeling, Virtual Screening, and Molecular Docking Simulation Approaches Identified Potential Lead Compounds against Pancreatic Cancer by Targeting FAK1. Pharmaceuticals (Basel) 2023;16. [PMID: 36678617 DOI: 10.3390/ph16010120] [Reference Citation Analysis]
3 Yue J, Miao P, Li L, Yan R, Dong W, Mei Q. Injectable Carbon Dots-Based Hydrogel for Combined Photothermal Therapy and Photodynamic Therapy of Cancer. ACS Appl Mater Interfaces 2022. [DOI: 10.1021/acsami.2c15428] [Reference Citation Analysis]
4 Kosma K, Thalhammer S, Gruenberger T. Neoadjuvant treatment of pancreatic ductal adenocarcinoma. memo 2022;15:219-223. [DOI: 10.1007/s12254-022-00832-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lee W, Park HJ, Lee HJ, Jun E, Song KB, Hwang DW, Lee JH, Lim K, Kim N, Lee SS, Byun JH, Kim HJ, Kim SC. Preoperative data-based deep learning model for predicting postoperative survival in pancreatic cancer patients. Int J Surg 2022;:106851. [PMID: 36049618 DOI: 10.1016/j.ijsu.2022.106851] [Reference Citation Analysis]
6 Zheng L, Liu H. Prognostic association between NLRP3 inflammasome expression level and operable pancreatic adenocarcinoma. Int J Biol Markers 2022;:3936155221096690. [PMID: 35686324 DOI: 10.1177/03936155221096690] [Reference Citation Analysis]
7 Henry AC, Schouten TJ, Daamen LA, Walma MS, Noordzij P, Cirkel GA, Los M, Besselink MG, Busch OR, Bonsing BA, Bosscha K, van Dam RM, Festen S, Groot Koerkamp B, van der Harst E, de Hingh IHJT, Kazemier G, Liem MS, de Meijer VE, Nieuwenhuijs VB, Roos D, Schreinemakers JMJ, Stommel MWJ, Molenaar IQ, van Santvoort HC; Dutch Pancreatic Cancer Group. Short- and Long-Term Outcomes of Pancreatic Cancer Resection in Elderly Patients: A Nationwide Analysis. Ann Surg Oncol 2022. [PMID: 35653069 DOI: 10.1245/s10434-022-11831-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lu W, Wang L, Li X, Tang K. Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis. J Int Med Res 2022;50:3000605221093225. [PMID: 35481414 DOI: 10.1177/03000605221093225] [Reference Citation Analysis]